– UK, Northwich – Dechra Pharmaceuticals PLC (LON:DPH) today announced that, with effect from 1st February 2019, Lisa Bright will take up a new position as a Non-Executive Director of the Company.
Commenting on the appointment Tony Rice, Chairman, Dechra Pharmaceuticals said: “On behalf of the Board and all stakeholders I am delighted to welcome Lisa to Dechra. She brings significant healthcare sector experience and strong inter-personal skills which will be invaluable as we continue our international expansion strategy and develop our employee engagement interaction.”
Lisa’s appointment brings skills to the Board in strategic and operational leadership in global market leading pharmaceutical and emerging biotech companies gained over her 25 year career in the industry.
About Lisa Bright
Lisa is currently President International, and previously Chief Commercial and Corporate Affairs Officer of Intercept Pharmaceuticals, Inc, a global biopharmaceutical company focused on the development and commercialisation of novel therapeutics. Previously Lisa held various Vice President roles at Gilead Sciences, Inc and GlaxoSmithKline plc, in Regional General Management, Government Affairs, and sales and marketing. Lisa is also a Non-Executive Director at Ascendis Pharma.
About Dechra Pharmaceuticals PLC
Dechra is an international specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra’s business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.
For more information : https://www.dechra.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.